BMY

Bristol-Myers Squibb

Halal Rating :
Comfortable
Last Price $57.01 Last updated:
Market Cap $101.27b
7D Change -1.11%
1 Year Change 10.81%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NYSE
Next Earnings Date Oct. 31, 2024

Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines to treat serious diseases. The company's primary focus areas include oncology, hematology, immunology, cardiovascular disease, and fibrosis.

The company develops and markets prescription pharmaceuticals in various therapeutic areas, including cancer, cardiovascular disease, immune disorders, and fibrosis. Key products include Opdivo, Eliquis, Revlimid, and Pomalyst/Imnovid.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $11.89b $9.98b - - 0.00% 0.00%
June 30, 2024 $12.2b $10.64b - - 0.00% 0.00%
March 31, 2024 $11.87b $23.3b - - 0.00% 0.00%

Company Impact

Help us evaluate Bristol-Myers Squibb's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates